Shattuck Labs (STTK)


Market Price (11/21/2026): $4.46 | Market Cap: $454.2 MilSector: Health Care | Industry: Biotechnology

Shattuck Labs (STTK)


Market Price (11/21/2026): $4.46
Market Cap: $454.2 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.97

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -72 Mil

Stock price has recently run up significantly
12M Rtn12 month market price return is 131%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Key risks
STTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.97
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -72 Mil
5 Stock price has recently run up significantly
12M Rtn12 month market price return is 131%
6 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
8 Key risks
STTK key risks include [1] the unpredictable outcome of its clinical trials and subsequent regulatory approvals and [2] future liquidity needs, Show more.

STTK in ETFs

Weight = STTK's share of each fund

VTI0.00%
IWM0.01%
XBI0.09%
IWO0.02%
VTWO0.01%
VHT0.01%
IWN0.00%
DFAS0.00%
+2 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Nov 9: up 8.0% in one day (S&P 500 up 2.4%)
The stock rose without company news as the broader market also saw a significant rally. Major indexes like the Dow jumped, fueling a broad-based relief rally.

Down 44.7% since its Aug 25 high (S&P 500 down 9.7%)
The stock declined substantially over the period, with company news and a broader market downturn contributing. Significant drops occurred on October 13 after poster presentations, and on November 5 during earnings.

Nov 5: down 12.8% on its earnings report (S&P 500 down 4.4%)
The stock dropped after reporting its third quarter 2026 financial results, which showed no revenue and a $-25M net loss. This decline also occurred as the broader market fell, with headlines reporting a "sea of red."

Show more
Prices as of 11/20/2026

Nov 9: up 8.0% in one day (S&P 500 up 2.4%)
The stock rose without company news as the broader market also saw a significant rally. Major indexes like the Dow jumped, fueling a broad-based relief rally.

Down 44.7% since its Aug 25 high (S&P 500 down 9.7%)
The stock declined substantially over the period, with company news and a broader market downturn contributing. Significant drops occurred on October 13 after poster presentations, and on November 5 during earnings.

Nov 5: down 12.8% on its earnings report (S&P 500 down 4.4%)
The stock dropped after reporting its third quarter 2026 financial results, which showed no revenue and a $-25M net loss. This decline also occurred as the broader market fell, with headlines reporting a "sea of red."

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -36.9% change in STTK stock from 7/31/2026 to 11/20/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611202026Change
Stock Price ($)7.074.46-36.9%
Change Contribution By: 
Total Revenues ($ Mil)10 
P/S Multiple793.5∞9.2233720368547763E17%
Shares Outstanding (Mil)112183-38.7%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/20/2026
ReturnCorrelation
STTK-36.9% 
Market (SPY)-7.4%39.6%
Sector (XLV)9.5%30.8%

Fundamental Drivers

The -37.6% change in STTK stock from 4/30/2026 to 11/20/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611202026Change
Stock Price ($)7.154.46-37.6%
Change Contribution By: 
Total Revenues ($ Mil)10 
P/S Multiple743.8∞9.2233720368547763E17%
Shares Outstanding (Mil)104183-43.2%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/20/2026
ReturnCorrelation
STTK-37.6% 
Market (SPY)-3.5%26.1%
Sector (XLV)22.4%23.8%

Fundamental Drivers

The 132.3% change in STTK stock from 10/31/2025 to 11/20/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.
(LTM values as of)1031202511202026Change
Stock Price ($)1.924.46132.3%
Change Contribution By: 
Total Revenues ($ Mil)30 
P/S Multiple32.7∞9.2233720368547763E17%
Shares Outstanding (Mil)51183-72.2%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/20/2026
ReturnCorrelation
STTK132.3% 
Market (SPY)2.2%22.1%
Sector (XLV)24.9%14.5%

Fundamental Drivers

The 175.3% change in STTK stock from 10/31/2023 to 11/20/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.
(LTM values as of)1031202311202026Change
Stock Price ($)1.624.46175.3%
Change Contribution By: 
Total Revenues ($ Mil)10 
P/S Multiple80.1∞9.2233720368547763E17%
Shares Outstanding (Mil)42183-76.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/20/2026
ReturnCorrelation
STTK175.3% 
Market (SPY)71.0%19.3%
Sector (XLV)49.6%18.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
STTK Return-84%-73%210%-83%202%22%-91%
Peers Return36%21%2%8%26%27%190%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
STTK Win Rate25%17%58%42%58%55% 
Peers Win Rate62%62%43%47%60%62% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
STTK Max Drawdown-84%-78%-71%-91%-62%-51% 
Peers Max Drawdown-16%-18%-23%-21%-22%-16% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRK, ABBV, PFE, LLY, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventSTTKS&P 500
2025 US Tariff Shock
  % Loss-41.8%-18.8%
  % Gain to Breakeven71.9%23.1%
  Time to Breakeven3 days79 days
2024 Yen Carry Trade Unwind
  % Loss-18.9%-7.8%
  % Gain to Breakeven23.3%8.5%
  Time to Breakeven29 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.5%-9.5%
  % Gain to Breakeven90.5%10.5%
  Time to Breakeven71 days24 days
2023 SVB Regional Banking Crisis
  % Loss-44.4%-6.7%
  % Gain to Breakeven79.8%7.1%
  Time to Breakeven210 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-70.9%-24.5%
  % Gain to Breakeven243.2%32.4%
  Time to Breakeven438 days427 days

Compare to MRK, ABBV, PFE, LLY, JNJ

In The Past

Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventSTTKS&P 500
2025 US Tariff Shock
  % Loss-41.8%-18.8%
  % Gain to Breakeven71.9%23.1%
  Time to Breakeven3 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.5%-9.5%
  % Gain to Breakeven90.5%10.5%
  Time to Breakeven71 days24 days
2023 SVB Regional Banking Crisis
  % Loss-44.4%-6.7%
  % Gain to Breakeven79.8%7.1%
  Time to Breakeven210 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-70.9%-24.5%
  % Gain to Breakeven243.2%32.4%
  Time to Breakeven438 days427 days

Compare to MRK, ABBV, PFE, LLY, JNJ

In The Past

Shattuck Labs's stock fell -41.8% during the 2025 US Tariff Shock. Such a loss loss requires a 71.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Shattuck Labs (STTK)

Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company dedicated to developing novel therapeutic agents for severe medical conditions. Headquartered in Austin, Texas, the company's core focus is on creating treatments for both cancer and autoimmune diseases, currently advancing its product candidates through early-stage human clinical trials.

The company's lead product candidates are designed to address various forms of cancer. SL-172154 is currently in Phase 1 clinical trials for ovarian, fallopian tube, and peritoneal cancers. Concurrently, Shattuck Labs is developing SL-279252, also in Phase 1 trials, aimed at treating patients with advanced solid tumors and lymphoma. Ultimately, Shattuck Labs seeks to serve patients suffering from these challenging diseases by introducing innovative treatment solutions into the biotechnology market.

AI Analysis | Feedback

Here are a few analogies for Shattuck Labs:

  • A startup Amgen for cancer and autoimmune drug discovery.

  • Like a small, independent R&D lab for Pfizer or Merck, but focused on experimental drugs for cancer and autoimmune diseases.

AI Analysis | Feedback

```html
  • SL-172154: A therapeutic product candidate in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
  • SL-279252: A therapeutic product candidate in Phase 1 clinical trial for patients with advanced solid tumors and lymphoma.
```

AI Analysis | Feedback

Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and autoimmune diseases. As described, their lead product candidates are currently in Phase 1 clinical trials. This means the company is in the research and development phase and has not yet commercialized any products or services.

Therefore, Shattuck Labs does not have major customers in the traditional sense of companies or individuals purchasing their products or services.

AI Analysis | Feedback

null

AI Analysis | Feedback

Taylor H. Schreiber, MD, PhD Chief Executive Officer, Co-founder, and Director

Dr. Schreiber co-founded Shattuck Labs in 2016 and served as Chief Scientific Officer before his appointment as CEO in January 2020. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc., where he co-invented significant elements of their ImPACT and ComPACT technology platforms. He also co-invented TNFRSF25 agonist technology developed by Pelican Therapeutics, Inc., where he served as Chairman of the Scientific Advisory Board. Pelican Therapeutics was sold in 2017.

Andrew R. Neill Chief Financial Officer

Mr. Neill has served as Chief Financial Officer of Shattuck Labs since March 2021, having joined the company in 2017. He previously served as Vice President of Finance and Corporate Strategy, and Vice President of Corporate Development and Strategy. Prior to joining Shattuck, Mr. Neill was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. He played a key role in Shattuck's Series B and B-1 financings and initial public offering.

Lini Pandite, MD, MBA Chief Medical Officer

Dr. Pandite joined Shattuck Labs in July 2017 as Chief Medical Officer. She brings over 25 years of academic, medical, and pharmaceutical experience with broad expertise in oncology drug development, spanning from early-to-late phase development through registration and commercialization.

Suresh de Silva, PhD Chief Scientific Officer

Dr. de Silva has served as Chief Scientific Officer since January 2023. He joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform. He previously served as Vice President of Product Development and Executive Director of Research and Development. Prior to Shattuck, he was the Director of Research and Development at Heat Biologics, Inc., where he co-developed the ComPact cell-based vaccine platform.

Casi DeYoung Chief Business Officer

Ms. DeYoung has served as Chief Business Officer since December 2019. From June 2018 to December 2019, she served as Vice President and Chief Operating Officer for ImmuneSensor Therapeutics, an immunotherapy-focused biotechnology company, where she was responsible for corporate strategy, start-up operations, intellectual property, oversight of the company's first IND filing, and the initiation of a first-in-human Phase I clinical trial.

AI Analysis | Feedback

The key risks for Shattuck Labs (STTK), a clinical-stage biotechnology company, primarily revolve around the inherent uncertainties of drug development and commercialization in the highly regulated and competitive biotechnology sector.

  1. Clinical Trial Failure: Shattuck Labs' valuation and future prospects are heavily dependent on the successful outcome of its ongoing clinical trials, particularly for its lead product candidate, SL-325. There is no guarantee that preliminary data for SL-325, currently in Phase 1 for inflammatory bowel diseases (IBD), will be positive or viewed favorably by the market. The company has previously discontinued its SL-172154 oncology program due to "modest improvement" in overall survival, highlighting the tangible risk and impact of clinical trial failures, which can lead to significant financial losses and strategic shifts. Biotechnology development is characterized by high attrition rates and substantial development costs, making clinical success a paramount risk.

  2. Regulatory Approval Risk: As with all biotechnology companies, Shattuck Labs faces significant inherent risks associated with obtaining regulatory approvals for its drug candidates. The U.S. Food and Drug Administration (FDA) approval process is complex, lengthy, and never guaranteed, even with positive clinical data. Failure to comply with stringent regulatory requirements can result in severe penalties, delaying or preventing market access for potential therapies.

  3. Lack of Profitability and Dependence on Future Funding: Shattuck Labs is currently a clinical-stage company with no product revenue, operating with significant net losses and negative operating margins. While the company has extended its cash runway, anticipating sufficient capital into 2029, this projection is contingent upon the full exercise of outstanding common stock warrants. The biotechnology industry often faces challenges in raising capital, particularly in an uncertain economic landscape, making sustained profitability and access to future funding critical risks.

AI Analysis | Feedback

null

AI Analysis | Feedback

Shattuck Labs (STTK) was developing therapeutics for several cancer indications. While their lead product candidates, SL-172154 and SL-279252, were initially aimed at these markets, Shattuck Labs has since discontinued their clinical development for these specific oncology programs.

Here are the addressable market sizes for the indications that Shattuck Labs' main products were initially targeting:

SL-172154 (Discontinued Oncology Program)

SL-172154 was in Phase 1 clinical trials for the treatment of ovarian, fallopian tube, and peritoneal cancers. However, Shattuck Labs discontinued the SL-172154 clinical program in October 2024 due to modest improvements in median overall survival compared to benchmarks, and shifted focus to other programs.

  • Ovarian Cancer: The global ovarian cancer market size was valued at approximately USD 2.5 billion in 2025 and is projected to reach USD 5.8 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 9.21% from 2026 to 2034. North America is a leading region in this market.
  • Fallopian Tube Cancer: The global fallopian tube cancer treatment market size was valued at USD 1.80 billion in 2025 and is expected to reach USD 3.35 billion by 2033, growing at a CAGR of 8.10%. North America held the largest revenue share in this market in 2025. The global fallopian tube cancer therapeutics market size was also calculated at USD 1.93 billion in 2025 and is predicted to increase to approximately USD 5.41 billion by 2035, expanding at a CAGR of 10.86% from 2026 to 2035.
  • Peritoneal Cancer: Market sizes for primary peritoneal cancer are often integrated with those of ovarian and fallopian tube cancers due to their clinical similarities and shared treatment approaches.

SL-279252 (Discontinued Oncology Program)

SL-279252 was in Phase 1 clinical trials for advanced solid tumors and lymphoma. Shattuck Labs discontinued clinical development of SL-279252 in February 2023 because it did not observe an overall response rate necessary to justify continued development.

  • Advanced Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032, with a CAGR of 20.00% during the forecast period of 2025 to 2032. North America dominates the solid tumors market. Another source indicates the global solid tumor therapeutics market size reached USD 223.65 billion in 2026 and is forecast to reach USD 326.82 billion by 2031.
  • Lymphoma: The global lymphoma treatment market size was valued at USD 8.3 billion in 2024 and is expected to reach USD 18.3 billion by 2034, growing at a CAGR of 8.4% from 2025 to 2034. The U.S. lymphoma treatment market was valued at USD 2.9 billion in 2023 and is projected to reach USD 6.8 billion by 2034. North America held a dominant share of approximately 49% in the global lymphoma treatment market in 2024.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Shattuck Labs (STTK) over the next 2-3 years:

  1. Successful Clinical Development and Regulatory Progress of SL-325: Shattuck Labs has shifted its primary focus to SL-325, a Death Receptor 3 (DR3) antagonist antibody, for the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions. The company anticipated filing an Investigational New Drug (IND) application for SL-325 and initiating a Phase 1 clinical trial in the third quarter of 2025. Positive data from this ongoing Phase 1 trial and subsequent clinical development stages would be a key driver for future revenue, potentially leading to regulatory approvals and market entry.
  2. Strategic Partnerships and Licensing Agreements for SL-325: As a clinical-stage biotechnology company, a significant driver of future revenue growth could come from securing strategic collaborations or licensing agreements for SL-325. Successful early-stage clinical data for SL-325 could attract larger pharmaceutical partners, potentially resulting in upfront payments, milestone payments, and future royalties, which could contribute to revenue within the specified timeframe.
  3. Expansion of the DR3 Blocking Antibody Pipeline: Beyond SL-325, Shattuck Labs is also working on nominating additional lead DR3 bispecific development candidates. The successful advancement and diversification of its DR3 blocking antibody pipeline could create multiple future product opportunities and revenue streams in the long term, building upon the initial development of SL-325.

AI Analysis | Feedback

Share Repurchases

No information available regarding share repurchases or authorized future share repurchases over the last 3-5 years.

Share Issuance

  • Shattuck Labs sold shares of its common stock under an at-the-market offering facility, generating aggregate gross proceeds of $21.4 million in the first quarter of 2026.
  • The company's number of shares outstanding increased by 37.09% in one year.
  • As of February 28, 2026, cash, cash equivalents, and short-term investments totaled approximately $94.5 million, which included the $21.4 million in gross proceeds from at-the-market stock sales.

Inbound Investments

  • As a result of at-the-market stock sales in the first quarter of 2026, accounts advised by T. Rowe Price Investment Management, Inc. reported beneficial ownership exceeding 10% of Shattuck Labs' outstanding common stock.

Capital Expenditures

  • Shattuck Labs' capital expenditures in the last 12 months were -$71,000.
  • The company reported $0 in capital expenditures in the fourth quarter of 2025.

Peer Outperformance in Biotechnology

STTK has outperformed 67% of its 369 Biotechnology peers over 5Y. Among the peers that beat it are RYTM, MIRM and TGTX. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that STTK has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
94%
of 452 industry peers · 131.1% return
3Y
79%
of 400 industry peers · 94.8% return
5Y
67%
of 369 industry peers · -52.6% return
Biotechnology peers with revenue growth within 4pp of STTK's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
STTK Shattuck Labs 66.1% -12.1x 131.1%94.8%-52.6% —
RYTM Rhythm Pharmaceuticals 65.8% -40.0x 11.6%236.3%990.9% +1,043pp
MIRM Mirum Pharmaceuticals 69.3% -7.0x 39.0%200.4%512.7% +565pp
TGTX TG Therapeutics 69.7% 84.1x 108.0%414.1%159.5% +212pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is STTK's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 17.3%74.7%198.5% CAH 523% · MCK 396% · COR 198%
Health Care Services 20 30.7%20.5%14.0% RDNT 146% · HIMS 100% · DGX 92%
Managed Health Care 8 60.1%-12.7%-9.2% OSCR 140% · HQY 54% · ELV 2%
Health Care Facilities 26 13.2%13.0%-10.4% THC 240% · NHC 211% · EHC 187%
Health Care Equipment 50 -2.1%6.7%-19.0% GKOS 393% · UFPT 319% · TMDX 274%
Health Care Supplies 11 19.9%-4.3%-41.8% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 61 -16.1%-0.2%-42.0% LQDA 1178% · KNSA 670% · XERS 648%
Life Sciences Tools & Services 110 -25.7%-28.8%-76.5% AXGN 471% · MEDP 169% · NTRA 165%
Biotechnology ← 370 -35.9%-45.4%-85.2% ELVN 1310% · DNTH 1164% · TRVI 1159%
Health Care Technology 23 -26.4%-56.9%-86.5% VEEV -13% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

STTKMRKABBVPFELLYJNJMedian
NameShattuck.Merck AbbVie Pfizer Eli LillyJohnson . 
Mkt Price4.46134.02286.2627.421,346.12270.55202.29
Mkt Cap0.8330.8506.4156.31,200.6651.9418.6
Rev LTM067,37866,01463,62486,46299,33566,696
Op Inc LTM-726,20123,74916,62444,31525,52520,186
FCF LTM-5014,74618,87211,78611,68919,59513,266
FCF 3Y Avg-5414,21218,06010,1305,28319,10012,171
CFO LTM-5018,70320,08914,17330,64526,15919,396
CFO 3Y Avg-5418,01119,15312,83817,58025,17017,795

Growth & Margins

STTKMRKABBVPFELLYJNJMedian
NameShattuck.Merck AbbVie Pfizer Eli LillyJohnson . 
Rev Chg LTM-100.0%4.9%10.7%1.3%45.5%7.8%6.3%
Rev Chg 3Y Avg66.1%4.4%6.3%-2.9%39.4%5.9%6.1%
Rev Chg Q-100.0%4.7%10.3%-0.4%38.6%5.9%5.3%
QoQ Delta Rev Chg LTM-100.0%1.2%2.5%-0.1%8.5%1.4%1.3%
Op Inc Chg LTM-24.8%-72.3%65.3%-1.7%67.9%7.9%3.1%
Op Inc Chg 3Y Avg7.5%19.8%17.8%16.3%68.3%4.4%17.0%
Op Mgn LTM-9.2%36.0%26.1%51.3%25.7%26.1%
Op Mgn 3Y Avg-22.2%29.2%23.3%43.7%25.4%25.4%
QoQ Delta Op Mgn LTM--1.3%2.0%-0.6%1.5%-1.1%-0.6%
CFO/Rev LTM-27.8%30.4%22.3%35.4%26.3%27.8%
CFO/Rev 3Y Avg-27.7%31.7%20.6%25.7%27.1%27.1%
FCF/Rev LTM-21.9%28.6%18.5%13.5%19.7%19.7%
FCF/Rev 3Y Avg-21.9%29.9%16.2%6.3%20.6%20.6%

Valuation

STTKMRKABBVPFELLYJNJMedian
NameShattuck.Merck AbbVie Pfizer Eli LillyJohnson . 
Mkt Cap0.8330.8506.4156.31,200.6651.9418.6
P/S-4.97.72.513.96.66.6
P/Op Inc-11.353.321.39.427.125.523.4
P/EBIT-11.349.232.122.427.134.829.6
P/E-12.1134.849.038.843.540.542.0
P/CFO-16.517.725.211.039.224.921.3
Total Yield-8.3%3.3%4.4%8.9%2.8%4.4%3.8%
Dividend Yield0.0%2.5%2.4%6.3%0.5%2.0%2.2%
FCF Yield 3Y Avg-22.5%5.2%4.5%6.5%0.6%4.0%4.2%
D/E0.00.20.20.40.00.10.1
Net D/E-0.20.10.10.30.00.00.1

Returns

STTKMRKABBVPFELLYJNJMedian
NameShattuck.Merck AbbVie Pfizer Eli LillyJohnson . 
1M Rtn-20.1%-10.6%0.5%-6.8%6.1%5.0%-3.1%
3M Rtn-40.8%-11.6%8.7%-0.9%7.4%0.6%-0.1%
6M Rtn-26.9%10.9%34.5%9.3%26.7%16.7%13.8%
12M Rtn131.1%45.3%28.5%19.9%29.8%36.2%33.0%
3Y Rtn94.8%43.7%128.0%9.9%131.7%93.4%94.1%
1M Excs Rtn-17.1%-5.8%3.6%-5.3%6.4%4.3%-0.9%
3M Excs Rtn-40.5%-7.4%12.0%2.6%11.2%2.7%2.6%
6M Excs Rtn-26.1%11.7%35.2%10.1%27.5%17.4%14.6%
12M Excs Rtn115.9%33.5%14.9%5.9%17.4%24.9%21.2%
3Y Excs Rtn41.8%-20.0%65.1%-54.5%68.7%33.3%37.5%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Drug discovery and development162130
Total162130


Operating Income by Segment
$ Mil202520242023
Drug discovery and development-52-81-92
Total-52-81-92


Net Income by Segment
$ Mil202520242023
Drug discovery and development-49-75-87
Total-49-75-87


Price Behavior

Price Behavior
Market Price$4.46 
Market Cap ($ Bil)0.8 
First Trading Date10/09/2020 
Distance from 52W High-44.7% 
   50 Days200 Days
DMA Price$5.61$6.09
DMA Trenddownup
Distance from DMA-20.5%-26.7%
 3M1YR
Volatility64.1%78.0%
Downside Capture283.9478.77
Upside Capture78.67169.85
Correlation (S&P 500)40.6%23.2%
STTK Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.960.881.591.231.021.69
Up Beta-8.27-0.771.582.971.721.67
Down Beta-0.891.370.950.240.582.26
Up Capture39%14%113%67%200%368%
Bmk +ve Days12182862130427
Stock +ve Days10193060128363
Down Capture309%181%231%136%39%106%
Bmk -ve Days10253664121325
Stock -ve Days12233365118368

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STTK
STTK128.3%78.0%1.38-
Sector ETF (XLV)18.4%17.1%0.8014.8%
Equity (SPY)5.2%14.4%0.1122.4%
Gold (GLD)-13.9%29.3%-0.529.1%
Commodities (DBC)28.2%21.5%1.05-3.6%
Real Estate (VNQ)8.6%14.3%0.3315.6%
Bitcoin (BTCUSD)-32.4%43.7%-0.7813.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STTK
STTK-17.1%117.9%0.32-
Sector ETF (XLV)7.5%15.4%0.2918.4%
Equity (SPY)9.6%17.4%0.3920.6%
Gold (GLD)13.1%19.3%0.533.4%
Commodities (DBC)6.6%19.6%0.22-0.2%
Real Estate (VNQ)0.5%19.0%-0.0819.0%
Bitcoin (BTCUSD)-0.7%51.4%0.1712.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STTK
STTK-12.8%112.0%0.26-
Sector ETF (XLV)11.4%16.8%0.5515.7%
Equity (SPY)14.1%18.1%0.6619.0%
Gold (GLD)10.4%16.6%0.502.8%
Commodities (DBC)7.2%18.2%0.310.4%
Real Estate (VNQ)5.9%20.7%0.2417.2%
Bitcoin (BTCUSD)56.2%66.3%0.9611.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity10.7 Mil
Short Interest: % Change Since 101520262.9%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest12.0 days
Basic Shares Quantity183.2 Mil
Short % of Basic Shares5.9%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-12.8%-1.9% 
8/11/20260.6%3.5%-11.3%
5/7/2026-6.3%1.0%-31.4%
3/5/20267.8%24.3%35.7%
11/6/20251.0%-6.1%60.2%
8/14/20256.1%24.6%136.8%
5/1/2025-7.8%-13.0%-3.2%
11/14/202412.3%-9.0%-6.6%
...
SUMMARY STATS   
# Positive13810
# Negative111613
Median Positive4.4%8.7%13.3%
Median Negative-5.9%-6.9%-11.4%
Max Positive12.3%24.6%136.8%
Max Negative-28.6%-34.5%-50.6%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-12.8%-1.9% 
8/11/20260.6%3.5%-11.3%
5/7/2026-6.3%1.0%-31.4%
3/5/20267.8%24.3%35.7%
11/6/20251.0%-6.1%60.2%
8/14/20256.1%24.6%136.8%
5/1/2025-7.8%-13.0%-3.2%
11/14/202412.3%-9.0%-6.6%
8/1/2024-3.2%-19.1%-4.8%
5/2/20242.2%-3.4%-32.0%
2/29/202410.5%7.3%1.8%
11/9/2023-23.2%-8.9%0.0%
8/10/2023-2.3%-5.9%-1.4%
5/9/2023-2.1%-7.0%2.8%
2/23/20230.4%-9.5%-33.3%
11/8/2022-5.9%1.8%6.8%
8/11/2022-4.4%-6.7%-17.3%
5/12/20228.3%-5.8%27.3%
3/15/20223.3%12.8%-11.4%
11/9/2021-28.6%-34.5%-50.6%
8/11/20212.6%-3.1%-0.0%
5/10/20214.4%-1.8%5.2%
3/15/2021-2.4%-13.6%-13.2%
11/13/20207.5%10.1%19.9%
SUMMARY STATS   
# Positive13810
# Negative111613
Median Positive4.4%8.7%13.3%
Median Negative-5.9%-6.9%-11.4%
Max Positive12.3%24.6%136.8%
Max Negative-28.6%-34.5%-50.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/11/202610-Q
03/31/202605/07/202610-Q
12/31/202503/05/202610-K
09/30/202511/06/202510-Q
06/30/202508/14/202510-Q
03/31/202505/01/202510-Q
12/31/202403/27/202510-K
09/30/202411/14/202410-Q
06/30/202408/01/202410-Q
03/31/202405/02/202410-Q
12/31/202302/29/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202202/23/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/11/202610-Q
03/31/202605/07/202610-Q
12/31/202503/05/202610-K
09/30/202511/06/202510-Q
06/30/202508/14/202510-Q
03/31/202505/01/202510-Q
12/31/202403/27/202510-K
09/30/202411/14/202410-Q
06/30/202408/01/202410-Q
03/31/202405/02/202410-Q
12/31/202302/29/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/09/202310-Q
12/31/202202/23/202310-K
09/30/202211/09/202210-Q
06/30/202208/11/202210-Q
03/31/202205/12/202210-Q
12/31/202103/15/202210-K
09/30/202111/09/202110-Q
06/30/202108/12/202110-Q
03/31/202105/10/202110-Q
12/31/202003/16/202110-K
09/30/202011/13/202010-Q
06/30/202010/13/2020424B4

Insider Activity

Updated 7/7/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Shukla, Abhinav AChief Technical OfficerDirectSell70720267.014102,874605,524Form
2Shukla, Abhinav AChief Technical OfficerDirectSell70220267.07100707610,707Form
3Shukla, Abhinav AChief Technical OfficerDirectSell70220267.0823,365165,424611,570Form
4Pandite, Arundathy NChief Medical OfficerDirectSell70220267.0130,000210,300954,895Form
5Siegall, Clay B DirectBuy61120264.0062,500250,0001,274,432Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Shukla, Abhinav AChief Technical OfficerDirectSell70720267.014102,874605,524Form
2Shukla, Abhinav AChief Technical OfficerDirectSell70220267.07100707610,707Form
3Shukla, Abhinav AChief Technical OfficerDirectSell70220267.0823,365165,424611,570Form
4Pandite, Arundathy NChief Medical OfficerDirectSell70220267.0130,000210,300954,895Form
5Siegall, Clay B DirectBuy61120264.0062,500250,0001,274,432Form
6Shukla, Abhinav AChief Technical OfficerDirectSell51420267.012,03214,244569,619Form
7Pandite, Arundathy NChief Medical OfficerDirectSell51420266.6130,000198,3001,098,708Form
8Orbimed, Advisors LlcSee FootnoteBuy90220250.876,306,1275,471,8264,559,855Form
9Ashiya, MonaSee FootnoteBuy90220250.876,306,1275,471,8264,559,855Form

Investor Activity (13F)

Updated Nov 21, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Prosight Management, LP$32.2 Mil5.3%46ADD +110.1%13F
Redmile Group, LLC$35.6 Mil2.4%35Hold13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Prosight Management, LP$32.2 Mil5.3%46ADD +110.1%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Redmile Group, LLC$35.6 Mil2.4%35Hold13F
Prosight Management, LP$32.2 Mil5.3%46ADD +110.1%13F
Core Cache Last Updated: 11/20/2026